Q-omics provides the consensus-scored KCNMB1 profile across patient tissues and cancer cell-line models. KCNMB1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, KCNMB1 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, KCNMB1 RNA expression shows 21,828 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight SKCM, BLCA, and UCEC as cancer lineages where KCNMB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNMB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNMB1 survival associations across molecular data types. KCNMB1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNMB1 RNA expression–survival associations across cancer types. High KCNMB1 expression shows unfavorable associations in KIRP, UVM and LAML, but favorable associations in SKCM, CESC and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for KCNMB1 RNA expression.
This table summarizes KCNMB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KCNMB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNMB1 shows lower tumor expression in BLCA, KICH, COAD and UCEC and higher tumor expression in KIRC and LIHC. The BLCA box plot shows higher KCNMB1 RNA expression in normal versus tumor tissue (log2 FC = −4.767, t-test p < 0.001).
This table shows molecular features associated with KCNMB1 in patient tissues and cancer cell lines. In patient samples, KCNMB1 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNMB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
